U.S. markets close in 26 minutes

Kraig Biocraft Laboratories, Inc. (KBLB)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1500-0.0100 (-6.25%)
As of 3:15PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1600
Open0.1585
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1500 - 0.1630
52 Week Range0.1100 - 0.3300
Volume647,754
Avg. Volume1,614,716
Market Cap128.162M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.0060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Kraig Biocraft Laboratories and Kings Group form Spydasilk Enterprises Pte. Ltd., a Singapore based Joint Venture Company, for the marketing and sales of spider silk based products

    Kraig’s joint venture with Kings is tied to the previously announced exclusive spider silk purchase and sales agreement valued at up to US$40 millionANN ARBOR, Mich., April 09, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company, together with M the Movement, Kings Golden Harvest Pte Ltd (“Kings Group”), has established Spydasilk Enterprises Pte. Ltd. (“Spydasilk Enterprises”) as a Singapore based joint venture. This partnership represents the Company’s first vertically integrated sales channel. Spydasilk Enterprises is developing a premium line of luxury streetwear based on Kraig Labs’ spider silk technologies with exclusive sales rights within the Association of Southeast Asian Nations (ASEAN) region. The move positions Kraig Labs and Kings Group to advance their partnership, which began with a previously announced exclusive purchase and sales agreement valued at up to US$40 million. “Based on our initial efforts, there is a definite demand for spider silk technology and product developers are very excited about working with these super fibers,” said Walter Wee, CIO of Kings Group. “In addition to building up the Spydasilk brand, we must build Spydasilk’s vendor and customer bases. We are already having great success with clients that share our vision and passion for spider silk. We believe that their efforts will further broaden Spydasilk’s market opportunities in multiple industries asides from the fashion industry,” continued Wee. The new joint venture company will commercialize Kraig Labs’ biodegradable and biocompatible ‘super fibers’, using a scalable and cost-effective spider silk production platform and patented spider silk gene sequences in silkworms. “This new joint venture is the beginning of the fulfillment of my original vision for Kraig Labs, where we are able to vertically integrate and capture intermediate and end product margins. Thanks to Walter and the Kings Group team, Spydasilk should hit the ground running. We have high expectations for the future of spider silk and Spydasilk Enterprises,” said Kim Thompson, Kraig Labs’ founder and CEO. To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news. About Kings Group and M the Movement Kings Group is headquartered in Singapore and established regional offices with multiple assets in Indonesia and Vietnam. Kings Group envisions itself to be a forerunner in International Marketing and Trading; bridging domestic businesses and projecting their products internationally. For further information, please visit www.kings.com.sg. M the Movement is Kings Group’s premiere eco-friendly luxury streetwear line. Internationally recognized and loved by celebrities globally. For more information, please visit www.mthemovement.com About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, LLC(720) 288-8495ir@KraigLabs.com

  • GlobeNewswire

    Kraig Biocraft Laboratories Secures $4 Million Dollars of Expansion Capital

    ANN ARBOR, Mich., March 26, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital. This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization and sale of recombinant spider silk. “This is a major financial milestone for Kraig. For many years we have operated on a shoestring budget, building a solid foundation with our spider silk production system. We are now prepared to reap the rewards of that careful investment with opportunities to put this capital to work building materials, products and brands,” said CEO and Founder, Kim Thompson. To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Ben Hansel, Hansel Capital, LLC(720) 288-8495ir@KraigLabs.com

  • GlobeNewswire

    Kraig Biocraft Laboratories Announces Expanded Spider Silk Protection with Patent Granted in Vietnam

    ANN ARBOR, Mich., March 15, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Vietnamese patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig . This patent plays a vital role in Kraig’s growing portfolio of spider silk Intellectual Property. The Company’s recombinant spider silk production is headquartered in central Vietnam. Patent number 26612, titled "A Chimeric Spider Silk Polypeptide, Composite Fiber Comprising the Polypeptide and Method of Making a Chimeric Spider Fiber" was issued to the University of Notre Dame (UND) under the Company's exclusive license agreement. Under the terms of that agreement, the Company paid for the development of the technology and the costs of patents issued to UND in exchange for exclusive global licensing rights. This patent provides protection for the Company's proprietary recombinant spider silk through September of 2031. With today’s announcement, the Company now expands protection for its spider silk technologies to include; Australia, South Korea, Canada, and Vietnam, with numerous other applications in other jurisdictions under review. “Recognition by the Vietnamese government of our specialized spider silk technologies opens new doors and opportunities for production expansion within Vietnam. Congratulations are in order for the researchers at the University of Notre Dame and Kraig for the breakthroughs that led to this patent. I would also offer a special thanks to our counsel at Workmann Nydegger, who have done an excellent job of spearheading Kraig’s IP filings,” said COO Jon Rice. “Our team at Kraig continues to prove that our vision for a cost-effective and environmentally responsible system for the mass commercialization of spider silk is now a reality.” To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news. About Kraig Biocraft Laboratories, Inc.: Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes,” "plans,” "expects,” "anticipates,” "foresees,” "estimated,” "hopes,” "if,” "develops,” "researching,” "research,” "pilot,” "potential,” "could" or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, LLC(720) 288-8495ir@KraigLabs.com